Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors (Q46612674)
Jump to navigation
Jump to search
scientific article published on 20 June 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors |
scientific article published on 20 June 2017 |
Statements
1 reference
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors (English)
1 reference
Mario Sznol
1 reference
Siwen Hu-Lieskovan
1 reference
Anthony W Tolcher
1 reference
Kyriakos P Papadopoulos
1 reference
Amita Patnaik
1 reference
Drew W Rasco
1 reference
Donna Di Gravio
1 reference
Bo Huang
1 reference
Dhiraj Gambhire
1 reference
Ying Chen
1 reference
Aron D Thall
1 reference
Nuzhat Pathan
1 reference
Emmett V Schmidt
1 reference
Laura Q M Chow
1 reference
20 June 2017
1 reference
23
1 reference
18
1 reference
5349-5357
1 reference